MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在手术中和手术后，进行静脉输液治疗以弥补血液和液体的损失是一种标准的程序。通常给出的液体是基于盐水的溶液。这些溶液分布在人体的血液和组织中。我们认为某些药物会影响静脉输液治疗的分布。这个项目的具体目标是找出是什么使液体从血液中流出进入组织，以及药物(β-肾上腺素能药物)可能如何影响这一点。我们将在短时间内测试静脉输液的效果。我们想知道有多少液体留在血液中，有多少液体进入组织。为了进行这项研究，需要对腿部进行一系列的血液样本和测量。这项研究的一部分是研究流体在正常状态下的分布情况。这项研究的另一个部分是观察当患者服用名为β-受体阻滞剂的药物或提高血压的药物(去甲肾上腺素)或增强心脏力量的药物(β-激动剂和米力农)时，体液分布是否发生变化。我们只招收年龄在18岁到50岁之间的健康人。根据一位统计学家的确定，总共需要112项研究。研究结果将1)促进对液体疗法的更好理解；2)帮助理解某些药物如何影响液体疗法；3)帮助制定更好的液体疗法计划，从而减少疾病和死亡。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During and after surgery it is a standard procedure to administer intravenous fluid therapy to replace blood and fluid losses. Fluids normally given are saline-based solutions. These solutions distribute into the blood and tissues of the body. We suggest that certain medicines affect the distribution of intravenous fluid therapy. The specific aims of this project are to find out what makes fluid to move out from the blood into the tissues and how medicines (beta-adrenergic agents) may affect this. We will test the effect of intravenous fluid given over a short period of time. We want to know how much of the fluid stays in the blood and how much fluid goes into the tissues. In order to do this study, a series of blood samples and measurements are needed from the leg. One part of this study is to study how fluids distribute in a normal state. Another part of this study is to see if distribution of fluid changes when patients are given medications called beta-blocker or drugs that increase blood pressure (norepineprine) or drugs that increase heart strength (beta-agonists and milrinone). We will enroll only healthy people between the ages of 18 and 50 years. As determined by a statistician, a total of 112 studies will be needed. The results will 1) promote a better understanding of fluid therapy 2)help understand how certain medicines impact fluid therapy 3) help develop a better fluid therapy plan that may decrease illness and death.